drugset / Trial / NCT00828204

Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects

NCT00828204

Phase 3 Completed 95 enrolled Biogen
NaSingle-groupOpen-label

Summary

The primary objective of the study was to evaluate the safe and effective use of the single-use autoinjector for the intramuscular (IM) delivery of liquid Avonex® (interferon beta-1a) in participants with multiple sclerosis (MS).

Timeline

Start
2009-01
Primary completion
2010-07
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Interferon beta-1a Protein / enzyme biologic 30 ug Intramuscular

Indications